deltatrials
Completed PHASE2 NCT00002471

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Leukemia Lymphoma
Interventions asparaginase cyclophosphamide cytarabine daunorubicin hydrochloride dexamethasone etoposide leucovorin calcium methotrexate methylprednisolone therapeutic hydrocortisone thiotepa vincristine sulfate
Updated 5 times since 2017 Last updated: Jun 19, 2013 Started: Feb 28, 1990 Primary completion: Jan 31, 2003 Completion: Jan 31, 2003

Listed as NCT00002471, this PHASE2 trial focuses on Leukemia and Lymphoma and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 5 times since 1990, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Feb 1990

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Ann Arbor, United States
  • • New York, United States
  • • Philadelphia, United States